Precision medicine of aneurysmal subarachnoid hemorrhage, vasospasm and delayed cerebral ischemia

References

• Council NR. Toward precision medicine: building a knowledge network for biomedical research and a new taxonomy of disease. Washington, DC: The National Academies Press; 2011. [cited 2016 June 29]. Available from: https://www.nap.edu/login.php?record_id=13284&page=http%3A%2F%2Fwww.nap.edu%2Fdownload%2F13284.
   Google Scholar
• Ashley EA, Butte AJ, Wheeler MT, et al. Clinical assessment incorporating a personal genome. Lancet. 2010;375:1525–1535.
   PubMed Web of Science ®Google Scholar
• Topol EJ. Individualized medicine from prewomb to tomb. Cell. 2014;157:241–253.
   PubMed Web of Science ®Google Scholar
• Suarez JI, Tarr RW, Selman WR. Aneurysmal subarachnoid hemorrhage. N Engl J Med. 2006;254(4):387–396.
   Web of Science ®Google Scholar
• Broderick JP, Brott TG, Duldner JE, et al. Initial and recurrent bleeding are the major causes of death following subarachnoid hemorrhage. Stroke. 1994;25(7):1342–1347.
   PubMed Web of Science ®Google Scholar
• Ostrowski RP, Colohan AR, Zhang JH. Molecular mechanisms of early brain injury after subarachnoid hemorrhage. Neurol Res. 2006;28:399–414.
   PubMed Web of Science ®Google Scholar
• Connolly ES Jr., Rabinstein AA, Carhuapoma JR, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American heart association/American stroke association. Stroke. 2012;43:1711–1737.
   PubMed Web of Science ®Google Scholar
• Hanggi D, Etminan N, Macdonald RL, et al. NEWTON: nimodipine microparticles to enhance recovery while reducing toxicity after subarachnoid hemorrhage. Neurocrit Care. 2015;23:274–284.
   PubMed Web of Science ®Google Scholar
• Ko SB. Multimodality monitoring in the neurointensive care unit: a special perspective for patients with stroke. J Stroke. 2013;15:99–108.
   PubMed Web of Science ®Google Scholar
• Maroon JC, Nelson PB. Hypovolemia in patients with subarachnoid hemorrhage: therapeutic implications. Neurosurgery. 1979;4:223–226.
   PubMed Web of Science ®Google Scholar
• Sehba FA, Mostafa G, Knopman J, et al. Acute alterations in microvascular basal lamina after subarachnoid hemorrhage. J Neurosurg. 2004;101:633–640.
   PubMed Web of Science ®Google Scholar
• Friedrich V, Flores R, Muller A, et al. Escape of intraluminal platelets into brain parenchyma after subarachnoid hemorrhage. Neuroscience. 2010;165:968–975.
   PubMed Web of Science ®Google Scholar
• Koide M, Penar PL, Tranmer BI, et al. Heparin-binding EGF-like growth factor mediates oxyhemoglobin-induced suppression of voltage-dependent potassium channels in rabbit cerebral artery myocytes. Am J Physiol Heart Circ Physiol. 2007;293:H1750- H1759.
   PubMed Web of Science ®Google Scholar
• Kim-Shapiro DB, Schechter AN, Gladwin MT. Unraveling the reactions of nitric oxide, nitrite, and hemoglobin in physiology and therapeutics. Arterioscler Thromb Vasc Biol. 2006;26:697–705.
   PubMed Web of Science ®Google Scholar
• Luo J, Martinez J, Yin X, et al. Hypoxia induces angiogenic factors in brain microvascular endothelial cells. Microvasc Res. 2012;83:138–145.
   PubMed Web of Science ®Google Scholar
• Xie A, Aihara Y, Bouryi VA, et al. Novel mechanism of endothelin-1-induced vasospasm after subarachnoid hemorrhage. J Cereb Blood Flow Metab. 2007;27:1692–1701.
   PubMed Web of Science ®Google Scholar
• Fujimori A, Yanagisawa M, Saito A, et al. Endothelin in plasma and cerebrospinal fluid of patients with subarachnoid haemorrhage. Lancet. 1990;336:633.
   PubMed Web of Science ®Google Scholar
• Hasan D, Vermeulen M, Wijdicks EF, et al. Effect of fluid intake and antihypertensive treatment on cerebral ischemia after subarachnoid hemorrhage. Stroke. 1989;20:1511–1515.
   PubMed Web of Science ®Google Scholar
• Rinkel GJ, Feigin VL, Algra A, et al. Circulatory volume expansion therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev. 2004;4:CD000483.
   Google Scholar
• Dorhout Mees SM, Rinkel GJ, Feigin VL, et al. Calcium antagonists for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev. 2007;3:CD000277.
   Google Scholar
• Sandow N, Diesing D, Sarrafzadeh A, et al. Nimodipine dose reductions in the treatment of patients with aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2015 doi:10.1007/s12028-015-0230-x. [Epub ahead of print].
   PubMed Web of Science ®Google Scholar
• Megyesi JF, Findlay JM, Vollrath B, et al. In vivo angioplasty prevents the development of vasospasm in canine carotid arteries. Pharmacological and morphological analyses. Stroke. 1997;28:1216–1224.
   PubMed Web of Science ®Google Scholar
• Megyesi JF, Vollrath B, Cook DA, et al. Long-term effects of in vivo angioplasty in normal and vasospastic canine carotid arteries: pharmacological and morphological analyses. J Neurosurg. 1999;91:100–108.
   PubMed Web of Science ®Google Scholar
• Honma Y, Fujiwara T, Irie K, et al. Morphological changes in human cerebral arteries after percutaneous transluminal angioplasty for vasospasm caused by subarachnoid hemorrhage. Neurosurgery. 1995;36:1073–1080; discussion 80-1.
   PubMed Web of Science ®Google Scholar
• Zwienenberg-Lee M, Hartman J, Rudisill N, et al. Effect of prophylactic transluminal balloon angioplasty on cerebral vasospasm and outcome in patients with Fisher grade III subarachnoid hemorrhage: results of a phase II multicenter, randomized, clinical trial. Stroke. 2008;39:1759–1765.
   PubMed Web of Science ®Google Scholar
• Baggott CD, Aagaard-Kienitz B. Cerebral vasospasm. Neurosurg Clin N Am. 2014;25:497–528.
   PubMed Web of Science ®Google Scholar
• Kimball MM, Velat GJ, Hoh BL. Critical care guidelines on the endovascular management of cerebral vasospasm. Neurocrit Care. 2011;15:336–341.
   PubMed Web of Science ®Google Scholar
• Eskridge JM, Song JK. A practical approach to the treatment of vasospasm. AJNR Am J Neuroradiol. 1997;18:1653–1660.
   PubMed Web of Science ®Google Scholar
• Eskridge JM, Song JK, Elliott JP, et al. Balloon angioplasty of the A1 segment of the anterior cerebral artery narrowed by vasospasm. Technical note. J Neurosurg. 1999;91:153–156.
   PubMed Web of Science ®Google Scholar
• Klimo P Jr., Kestle JR, MacDonald JD, et al. Marked reduction of cerebral vasospasm with lumbar drainage of cerebrospinal fluid after subarachnoid hemorrhage. J Neurosurg. 2004;100:215–224.
   PubMed Web of Science ®Google Scholar
• Al-Tamimi YZ, Bhargava D, Feltbower RG, et al. Lumbar drainage of cerebrospinal fluid after aneurysmal subarachnoid hemorrhage: a prospective, randomized, controlled trial (LUMAS). Stroke. 2012;43:677–682.
   PubMed Web of Science ®Google Scholar
• Wolf S. Rationale for lumbar drains in aneurysmal subarachnoid hemorrhage. Curr Opin Crit Care. 2015;21:120–126.
   PubMed Web of Science ®Google Scholar
• Macdonald RL. Delayed neurological deterioration after subarachnoid haemorrhage. Nat Rev Neurol. 2014;10:44–58.
   PubMed Web of Science ®Google Scholar
• Dorhout Mees SM, van den Bergh WM, Algra A, et al. Antiplatelet therapy for aneurysmal subarachnoid haemorrhage. Cochrane Database Syst Rev. 2007;4:CD006184.
   Google Scholar
• Treggiari MM, Walder B, Suter PM, et al. Systematic review of the prevention of delayed ischemic neurological deficits with hypertension, hypervolemia, and hemodilution therapy following subarachnoid hemorrhage. J Neurosurg. 2003;98:978–984.
   PubMed Web of Science ®Google Scholar
• Dankbaar JW, Slooter AJ, Rinkel GJ, et al. Effect of different components of triple-H therapy on cerebral perfusion in patients with aneurysmal subarachnoid haemorrhage: a systematic review. Crit Care. 2010;14:R23.
   Google Scholar
• Harrigan MR. Hypertension may be the most important component of hyperdynamic therapy in cerebral vasospasm. Crit Care. 2010;14:151.
   PubMed Web of Science ®Google Scholar
• Diringer MN, Bleck TP, Claude Hemphill J 3rd, et al. Critical care management of patients following aneurysmal subarachnoid hemorrhage: recommendations from the neurocritical care society’s multidisciplinary consensus conference. Neurocrit Care. 2011;15:211–240.
   PubMed Web of Science ®Google Scholar
• Gathier CS, van den Bergh WM, Slooter AJ. HIMALAIA (Hypertension Induction in the Management of AneurysmaL subArachnoid haemorrhage with secondary IschaemiA): a randomized single-blind controlled trial of induced hypertension vs. no induced hypertension in the treatment of delayed cerebral ischemia after subarachnoid hemorrhage. Int J Stroke. 2014;9:375–380.
   PubMed Web of Science ®Google Scholar
• Egge A, Waterloo K, Sjoholm H, et al. Prophylactic hyperdynamic postoperative fluid therapy after aneurysmal subarachnoid hemorrhage: a clinical, prospective, randomized, controlled study. Neurosurgery. 2001;49:593–605; discussion −6.
   PubMed Web of Science ®Google Scholar
• Lennihan L, Mayer SA, Fink ME, et al. Effect of hypervolemic therapy on cerebral blood flow after subarachnoid hemorrhage: a randomized controlled trial. Stroke. 2000;31:383–391.
   PubMed Web of Science ®Google Scholar
• Ekelund A, Reinstrup P, Ryding E, et al. Effects of iso- and hypervolemic hemodilution on regional cerebral blood flow and oxygen delivery for patients with vasospasm after aneurysmal subarachnoid hemorrhage. Acta Neurochir (Wien). 2002;144:703-712; discussion 12-3.
   PubMed Web of Science ®Google Scholar
• Abla AA, Lawton MT. Variability in endovascular treatment of delayed cerebral ischemia and vasospasm in aneurysmal subarachnoid hemorrhage. World Neurosurg. 2015;84:625–626.
   PubMed Web of Science ®Google Scholar
• Frontera JA, Fernandez A, Schmidt JM, et al. Clinical response to hypertensive hypervolemic therapy and outcome after subarachnoid hemorrhage. Neurosurgery. 2010;66:35-41; discussion.
   PubMed Web of Science ®Google Scholar
• Stuart RM, Helbok R, Kurtz P, et al. High-dose intra-arterial verapamil for the treatment of cerebral vasospasm after subarachnoid hemorrhage: prolonged effects on hemodynamic parameters and brain metabolism. Neurosurgery. 2011;68:337-345; discussion 45.
   PubMed Web of Science ®Google Scholar
• Hockel K, Diedler J, Steiner J, et al. Long-term, continuous intra-arterial nimodipine treatment of severe vasospasm following aneurysmal subarachnoid hemorrhage. World Neurosurg. 2016;88:104–112.
   PubMed Web of Science ®Google Scholar
• Scaravilli V, Tinchero G, Citerio G. Fever management in SAH. Neurocrit Care. 2011;15:287–294.
   PubMed Web of Science ®Google Scholar
• Wartenberg KE, Schmidt JM, Claassen J, et al. Impact of medical complications on outcome after subarachnoid hemorrhage. Crit Care Med. 2006;34:617-623;quiz 24.
   PubMed Web of Science ®Google Scholar
• Schiefecker AJ, Pfausler B, Beer R, et al. Parenteral diclofenac infusion significantly decreases brain-tissue oxygen tension in patients with poor-grade aneurysmal subarachnoid hemorrhage. Crit Care. 2013;17:R88.
   Google Scholar
• Goodson K, Lapointe M, Monroe T, et al. Intraventricular nicardipine for refractory cerebral vasospasm after subarachnoid hemorrhage. Neurocrit Care. 2008;8:247–252.
   PubMed Web of Science ®Google Scholar
• Webb A, Kolenda J, Martin K, et al. The effect of intraventricular administration of nicardipine on mean cerebral blood flow velocity measured by transcranial Doppler in the treatment of vasospasm following aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2010;12:159–164.
   PubMed Web of Science ®Google Scholar
• Lu N, Jackson D, Luke S, et al. Intraventricular nicardipine for aneurysmal subarachnoid hemorrhage related vasospasm: assessment of 90 days outcome. Neurocrit Care. 2012;16:368–375.
   PubMed Web of Science ®Google Scholar
• Ko SB, Choi HA, Helbok R, et al. Acute effects of intraventricular nicardipine on cerebral hemodynamics: a preliminary finding. Clin Neurol Neurosurg. 2016;144:48–52.
   PubMed Web of Science ®Google Scholar
• Sabri M, Macdonald RL. Statins: a potential therapeutic addition to treatment for aneurysmal subarachnoid hemorrhage? World Neurosurg. 2010;73:646–653.
   PubMed Web of Science ®Google Scholar
• Tseng MY. Summary of evidence on immediate statins therapy following aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2011;15:298–301.
   PubMed Web of Science ®Google Scholar
• Vergouwen MD, Frijns CJ, Roos YB, et al. Plasminogen activator inhibitor-1 4G allele in the 4G/5G promoter polymorphism increases the occurrence of cerebral ischemia after aneurysmal subarachnoid hemorrhage. Stroke. 2004;35:1280–1283.
   PubMed Web of Science ®Google Scholar
• Senbokuya N, Kinouchi H, Kanemaru K, et al. Effects of cilostazol on cerebral vasospasm after aneurysmal subarachnoid hemorrhage: a multicenter prospective, randomized, open-label blinded end point trial. J Neurosurg. 2013;118:121–130.
   PubMed Web of Science ®Google Scholar
• Niu PP, Yang G, Xing YQ, et al. Effect of cilostazol in patients with aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. J Neurol Sci. 2014;336:146–151.
   PubMed Web of Science ®Google Scholar
• Matsuda N, Naraoka M, Ohkuma H, et al. Effect of cilostazol on cerebral vasospasm and outcome in patients with aneurysmal subarachnoid hemorrhage: a randomized, double-blind, placebo-controlled trial. Cerebrovasc Dis. 2016;42:97–105.
   PubMed Web of Science ®Google Scholar
• Nowak L, Bregestovski P, Ascher P, et al. Magnesium gates glutamate-activated channels in mouse central neurones. Nature. 1984;307:462–465.
   PubMed Web of Science ®Google Scholar
• Dorhout Mees SM, Algra A, Vandertop WP, et al. Magnesium for aneurysmal subarachnoid haemorrhage (MASH-2): a randomised placebo-controlled trial. Lancet. 2012;380:44–49.
   PubMed Web of Science ®Google Scholar
• Siest G, Pillot T, Regis-Bailly A, et al. Apolipoprotein E: an important gene and protein to follow in laboratory medicine. Clin Chem. 1995;41:1068–1086.
   PubMed Web of Science ®Google Scholar
• Eichner JE, Dunn ST, Perveen G, et al. Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. Am J Epidemiol. 2002;155:487–495.
   PubMed Web of Science ®Google Scholar
• Laskowitz DT, Horsburgh K, Roses AD. Apolipoprotein E and the CNS response to injury. J Cereb Blood Flow Metab. 1998;18:465–471.
   PubMed Web of Science ®Google Scholar
• Lanterna LA, Ruigrok Y, Alexander S, et al. Meta-analysis of APOE genotype and subarachnoid hemorrhage: clinical outcome and delayed ischemia. Neurology. 2007;69:766–775.
   PubMed Web of Science ®Google Scholar
• Juvela S, Siironen J, Lappalainen J. Apolipoprotein E genotype and outcome after aneurysmal subarachnoid hemorrhage. J Neurosurg. 2009;110:989–995.
   PubMed Web of Science ®Google Scholar
• Gallek MJ, Conley YP, Sherwood PR, et al. APOE genotype and functional outcome following aneurysmal subarachnoid hemorrhage. Biol Res Nurs. 2009;10:205–212.
   PubMed Web of Science ®Google Scholar
• Lynch JR, Tang W, Wang H, et al. APOE genotype and an ApoE-mimetic peptide modify the systemic and central nervous system inflammatory response. J Biol Chem. 2003;278:48529–48533.
   PubMed Web of Science ®Google Scholar
• Gao J, Wang H, Sheng H, et al. A novel apoE-derived therapeutic reduces vasospasm and improves outcome in a murine model of subarachnoid hemorrhage. Neurocrit Care. 2006;4:25–31.
   PubMed Web of Science ®Google Scholar
• Wu HT, Ruan J, Zhang XD, et al. Association of promoter polymorphism of apolipoprotein E gene with cerebral vasospasm after spontaneous SAH. Brain Res. 2010;1362:112–116.
   PubMed Web of Science ®Google Scholar
• Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev. 1991;43:109–142.
   PubMed Web of Science ®Google Scholar
• Khurana VG, Sohni YR, Mangrum WI, et al. Endothelial nitric oxide synthase gene polymorphisms predict susceptibility to aneurysmal subarachnoid hemorrhage and cerebral vasospasm. J Cereb Blood Flow Metab. 2004;24:291–297.
   PubMed Web of Science ®Google Scholar
• Starke RM, Kim GH, Komotar RJ, et al. Endothelial nitric oxide synthase gene single-nucleotide polymorphism predicts cerebral vasospasm after aneurysmal subarachnoid hemorrhage. J Cereb Blood Flow Metab. 2008;28:1204–1211.
   PubMed Web of Science ®Google Scholar
• Ko NU, Rajendran P, Kim H, et al. Endothelial nitric oxide synthase polymorphism (−786T->C) and increased risk of angiographic vasospasm after aneurysmal subarachnoid hemorrhage. Stroke. 2008;39:1103–1108.
   PubMed Web of Science ®Google Scholar
• Giannopoulos S, Katsanos AH, Tsivgoulis G, et al. Statins and cerebral hemodynamics. J Cereb Blood Flow Metab. 2012;32:1973–1976.
   PubMed Web of Science ®Google Scholar
• Kirkpatrick PJ, Turner CL, Smith C, et al. Simvastatin in aneurysmal subarachnoid haemorrhage (STASH): a multicentre randomised phase 3 trial. Lancet Neurol. 2014;13:666–675.
   PubMed Web of Science ®Google Scholar
• Levy AP, Levy JE, Kalet-Litman S, et al. Haptoglobin genotype is a determinant of iron, lipid peroxidation, and macrophage accumulation in the atherosclerotic plaque. Arterioscler Thromb Vasc Biol. 2007;27:134–140.
   PubMed Web of Science ®Google Scholar
• Rother RP, Bell L, Hillmen P, et al. The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease. Jama. 2005;293:1653–1662.
   PubMed Web of Science ®Google Scholar
• Langlois MR, Delanghe JR. Biological and clinical significance of haptoglobin polymorphism in humans. Clin Chem. 1996;42:1589–1600.
   PubMed Web of Science ®Google Scholar
• Ohnishi H, Iihara K, Kaku Y, et al. Haptoglobin phenotype predicts cerebral vasospasm and clinical deterioration after aneurysmal subarachnoid hemorrhage. J Stroke Cerebrovasc Dis. 2013;22:520–526.
   PubMed Web of Science ®Google Scholar
• Chaichana KL, Levy AP, Miller-Lotan R, et al. Haptoglobin 2-2 genotype determines chronic vasospasm after experimental subarachnoid hemorrhage. Stroke. 2007;38:3266–3271.
   PubMed Web of Science ®Google Scholar
• Borsody M, Burke A, Coplin W, et al. Haptoglobin and the development of cerebral artery vasospasm after subarachnoid hemorrhage. Neurology. 2006;66:634–640.
   PubMed Web of Science ®Google Scholar
• Leclerc JL, Blackburn S, Neal D, et al. Haptoglobin phenotype predicts the development of focal and global cerebral vasospasm and may influence outcomes after aneurysmal subarachnoid hemorrhage. Proc Natl Acad Sci USA. 2015;112:1155–1160.
   PubMed Web of Science ®Google Scholar
• Garzon-Muvdi T, Pradilla G, Ruzevick JJ, et al. A glutamate receptor antagonist, S-4-carboxyphenylglycine (S-4-CPG), inhibits vasospasm after subarachnoid hemorrhage in haptoglobin 2-2 mice [corrected]. Neurosurgery. 2013;73:719-728; discussion 29.
   PubMed Web of Science ®Google Scholar
• Pradilla G, Garzon-Muvdi T, Ruzevick JJ, et al. Systemic L-citrulline prevents cerebral vasospasm in haptoglobin 2-2 transgenic mice after subarachnoid hemorrhage. Neurosurgery. 2012;70:747-756; discussion 56-7.
   Web of Science ®Google Scholar
• Froehler MT, Kooshkabadi A, Miller-Lotan R, et al. Vasospasm after subarachnoid hemorrhage in haptoglobin 2-2 mice can be prevented with a glutathione peroxidase mimetic. J Clin Neurosci. 2010;17:1169–1172.
   PubMed Web of Science ®Google Scholar
• Momin EN, Schwab KE, Chaichana KL, et al. Controlled delivery of nitric oxide inhibits leukocyte migration and prevents vasospasm in haptoglobin 2-2 mice after subarachnoid hemorrhage. Neurosurgery. 2009;65:937-945; discussion 45.
   PubMed Web of Science ®Google Scholar
• Marziali G, Rossi D, Giannini G, et al. cDNA cloning reveals a tissue specific expression of alternatively spliced transcripts of the ryanodine receptor type 3 (RyR3) calcium release channel. FEBS Lett. 1996;394:76–82.
   PubMed Web of Science ®Google Scholar
• Guerrero-Hernandez A, Gomez-Viquez L, Guerrero-Serna G, et al. Ryanodine receptors in smooth muscle. Front Biosci. 2002;7:d1676- d1688.
   Google Scholar
• Knot HJ, Nelson MT. Regulation of arterial diameter and wall [Ca2+] in cerebral arteries of rat by membrane potential and intravascular pressure. J Physiol. 1998;508(Pt 1):199–209.
   PubMed Web of Science ®Google Scholar
• Ledbetter MW, Preiner JK, Louis CF, et al. Tissue distribution of ryanodine receptor isoforms and alleles determined by reverse transcription polymerase chain reaction. J Biol Chem. 1994;269:31544–31551.
   PubMed Web of Science ®Google Scholar
• Majidi S, Grigoryan M, Tekle WG, et al. Intra-arterial dantrolene for refractory cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Neurocrit Care. 2012;17:245–249.
   PubMed Web of Science ®Google Scholar
• Muehlschlegel S, Carandang R, Hall W, et al. Dantrolene for cerebral vasospasm after subarachnoid haemorrhage: a randomised double blind placebo-controlled safety trial. J Neurol Neurosurg Psychiatry. 2015;86:1029–1035.
   PubMed Web of Science ®Google Scholar
• Rouch A, Vanucci-Bacque C, Bedos-Belval F, et al. Small molecules inhibitors of plasminogen activator inhibitor-1 - an overview. Eur J Med Chem. 2015;92:619–636.
   PubMed Web of Science ®Google Scholar
• Ladenvall C, Csajbok L, Nylen K, et al. Association between factor XIII single nucleotide polymorphisms and aneurysmal subarachnoid hemorrhage. J Neurosurg. 2009;110:475–481.
   PubMed Web of Science ®Google Scholar
• Suhardja A. Mechanisms of disease: roles of nitric oxide and endothelin-1 in delayed cerebral vasospasm produced by aneurysmal subarachnoid hemorrhage. Nat Clin Pract Cardiovasc Med. 2004;1:110-116; quiz 2 p following 6.
   PubMedGoogle Scholar
• Juvela S. Plasma endothelin concentrations after aneurysmal subarachnoid hemorrhage. J Neurosurg. 2000;92:390–400.
   PubMed Web of Science ®Google Scholar
• Mascia L, Fedorko L, Stewart DJ, et al. Temporal relationship between endothelin-1 concentrations and cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage. Stroke. 2001;32:1185–1190.
   PubMed Web of Science ®Google Scholar
• Fassbender K, Hodapp B, Rossol S, et al. Endothelin-1 in subarachnoid hemorrhage: an acute-phase reactant produced by cerebrospinal fluid leukocytes. Stroke. 2000;31:2971–2975.
   PubMed Web of Science ®Google Scholar
• Kramer A, Fletcher J. Do endothelin-receptor antagonists prevent delayed neurological deficits and poor outcomes after aneurysmal subarachnoid hemorrhage?: a meta-analysis. Stroke. 2009;40:3403–3406.
   PubMed Web of Science ®Google Scholar
• Ma J, Huang S, Ma L, et al. Endothelin-receptor antagonists for aneurysmal subarachnoid hemorrhage: an updated meta-analysis of randomized controlled trials. Crit Care. 2012;16:R198.
   Google Scholar
• Mathiesen T, Edner G, Ulfarsson E, et al. Cerebrospinal fluid interleukin-1 receptor antagonist and tumor necrosis factor-alpha following subarachnoid hemorrhage. J Neurosurg. 1997;87:215–220.
   PubMed Web of Science ®Google Scholar
• Wu W, Guan Y, Zhao G, et al. Elevated IL-6 and TNF-alpha levels in cerebrospinal fluid of subarachnoid hemorrhage patients. Mol Neurobiol. 2016;53(5):3277–3285.
   PubMed Web of Science ®Google Scholar
• Pan YX, Chen KF, Lin YX, et al. Intracisternal administration of SB203580, a p38 mitogen-activated protein kinase inhibitor, attenuates cerebral vasospasm via inhibition of tumor-necrosis factor-alpha. J Clin Neurosci. 2013;20:726–730.
   PubMed Web of Science ®Google Scholar
• Yagi K, Lidington D, Wan H, et al. Therapeutically targeting tumor necrosis factor-alpha/sphingosine-1-phosphate signaling corrects myogenic reactivity in subarachnoid hemorrhage. Stroke. 2015;46:2260–2270.
   PubMed Web of Science ®Google Scholar
• Gregory AP, Dendrou CA, Attfield KE, et al. TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. Nature. 2012;488:508–511.
   PubMed Web of Science ®Google Scholar
• Gruber A, Roessler K, Georgopoulos A, et al. Evaluation of big endothelin-1 concentrations in serum and ventricular cerebrospinal fluid after early surgical compared with nonsurgical management of ruptured intracranial aneurysms. Neurosurg Focus. 2000;8:e6.
   PubMedGoogle Scholar
• Burrell C, Luke S, Thapa P, et al. Proteomics as predictors of outcome in aneurysmal subarachnoid hemorrhage [Abstract]. Neurocrit Care. 2015;23:206.
   Google Scholar
• Dumont AS, Dumont RJ, Chow MM, et al. Cerebral vasospasm after subarachnoid hemorrhage: putative role of inflammation. Neurosurgery. 2003;53:123-133; discussion 33-5.
   PubMed Web of Science ®Google Scholar
• Schoch B, Regel JP, Wichert M, et al. Analysis of intrathecal interleukin-6 as a potential predictive factor for vasospasm in subarachnoid hemorrhage. Neurosurgery. 2007;60:828-836.
   PubMed Web of Science ®Google Scholar
• Hendryk S, Jarzab B, Josko J. Increase of the IL-1 beta and IL-6 levels in CSF in patients with vasospasm following aneurysmal SAH. Neuro Endocrinol Lett. 2004;25:141–147.
   PubMed Web of Science ®Google Scholar
• Kwon KY, Jeon BC. Cytokine levels in cerebrospinal fluid and delayed ischemic deficits in patients with aneurysmal subarachnoid hemorrhage. J Korean Med Sci. 2001;16:774–780.
   PubMed Web of Science ®Google Scholar
• Singh N, Hopkins SJ, Hulme S, et al. The effect of intravenous interleukin-1 receptor antagonist on inflammatory mediators in cerebrospinal fluid after subarachnoid haemorrhage: a phase II randomised controlled trial. J Neuroinflammation. 2014;11:1.
   PubMed Web of Science ®Google Scholar
• Simi A, Tsakiri N, Wang P, et al. Interleukin-1 and inflammatory neurodegeneration. Biochem Soc Trans. 2007;35:1122–1126.
   PubMed Web of Science ®Google Scholar
• Nylen K, Csajbok LZ, Ost M, et al. CSF -neurofilament correlates with outcome after aneurysmal subarachnoid hemorrhage. Neurosci Lett. 2006;404:132–136.
   PubMed Web of Science ®Google Scholar
• Petzold A, Keir G, Kay A, et al. Axonal damage and outcome in subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry. 2006;77:753–759.
   PubMed Web of Science ®Google Scholar
• McGirt MJ, Lynch JR, Blessing R, et al. Serum von Willebrand factor, matrix metalloproteinase-9, and vascular endothelial growth factor levels predict the onset of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Neurosurgery. 2002;51:1128-1134; discussion 34-5.
   PubMed Web of Science ®Google Scholar
• Tsurutani H, Ohkuma H, Suzuki S. Effects of thrombin inhibitor on thrombin-related signal transduction and cerebral vasospasm in the rabbit subarachnoid hemorrhage model. Stroke. 2003;34:1497–1500.
   PubMed Web of Science ®Google Scholar
• Kim GH, Kellner CP, Hahn DK, et al. Monocyte chemoattractant protein-1 predicts outcome and vasospasm following aneurysmal subarachnoid hemorrhage. J Neurosurg. 2008;109:38–43.
   PubMed Web of Science ®Google Scholar
• Lin CL, Dumont AS, Calisaneller T, et al. Monoclonal antibody against E selectin attenuates subarachnoid hemorrhage-induced cerebral vasospasm. Surg Neurol. 2005;64:201-205; discussion 5-6.
   Google Scholar
• Shimada N, Graf R, Rosner G, et al. Ischemia-induced accumulation of extracellular amino acids in cerebral cortex, white matter, and cerebrospinal fluid. J Neurochem. 1993;60:66–71.
   PubMed Web of Science ®Google Scholar
• Zhang H, Zhang X, Zhang T, et al. Excitatory amino acids in cerebrospinal fluid of patients with acute head injuries. Clin Chem. 2001;47:1458–1462.
   PubMed Web of Science ®Google Scholar
• Sarrafzadeh A, Haux D, Kuchler I, et al. Poor-grade aneurysmal subarachnoid hemorrhage: relationship of cerebral metabolism to outcome. J Neurosurg. 2004;100:400–406.
   PubMed Web of Science ®Google Scholar
• Jung CS, Lange B, Zimmermann M, et al. CSF and serum biomarkers focusing on cerebral vasospasm and ischemia after subarachnoid hemorrhage. Stroke Res Treat. 2013;2013:560305.
   PubMedGoogle Scholar
• Lin BF, Kuo CY, Wen LL, et al. Rosiglitazone attenuates cerebral vasospasm and provides neuroprotection in an experimental rat model of subarachnoid hemorrhage. Neurocrit Care. 2014;21:316–331.
   PubMed Web of Science ®Google Scholar
• Fadel MM, Foley PL, Kassell NF, et al. Histidine attenuates cerebral vasospasm in a rabbit model of subarachnoid hemorrhage. Surg Neurol. 1995;43:52-57; discussion 7-8.
   PubMedGoogle Scholar
• Platt SR, Coates JR, Eifler DM, et al. Effect of treatment with simvastatin and cyclosporine on neurotransmitter concentrations in cerebrospinal fluid after subarachnoid hemorrhage in dogs. Am J Vet Res. 2013;74:1111–1117.
   PubMed Web of Science ®Google Scholar
• Young B, Kalanuria A, Kumar M, et al. Cerebral microdialysis. Crit Care Nurs Clin North Am. 2016;28:109–124.
   PubMed Web of Science ®Google Scholar
• Johnston AJ, Gupta AK. Advanced monitoring in the neurology intensive care unit: microdialysis. Curr Opin Crit Care. 2002;8:121–127.
   PubMedGoogle Scholar